๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate

โœ Scribed by Paul Snell; Nisha Dave; Katie Wilson; Lucy Rowell; Angelica Weil; Lawrence Galitz; Richard Robson

Book ID
108640331
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
140 KB
Volume
59
Category
Article
ISSN
0306-5251

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Effect of milk on the pharmacokinetics o
Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers
โœ Kaori Morimoto; Kozue Kishimura; Takaaki Nagami; Nao Kodama; Yoichiro Ogama; Mid ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 240 KB ๐Ÿ‘ 1 views

We previously showed that oseltamivir, a prodrug of the influenza virus neuraminidase inhibitor Ro 64-0802, is a substrate of proton-coupled oligopeptide transporter (PEPT1), and its intestinal absorption in rats is markedly inhibited by administration with milk. To investigate the importance of PEP

Effect of mild and moderate hepatic impa
Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration
โœ Alfred E. Corey; Jeffrey R. Agnew; Eileen C. King; Nikhil J. Parekh; James H. Po ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 109 KB

Azimilide dihydrochloride (75-125 mg/day) is currently being developed for use in prolonging the time to recurrence of atrial fibrillation/flutter and for reducing the frequency of shocks in patients with an implantable cardioverting defibrillator. This study investigated the influence of mild and m